Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Validation of RP-HPLC Method for Determination of Omeprazole in Dissolution Media and Application to Study in-vitro Release from Solid- SNEDDS

Author(s): Suhair S. Al-Nimry*, Khouloud A. Alkhamis and Bashar M. Altaani

Volume 18, Issue 2, 2022

Published on: 21 January, 2021

Page: [208 - 217] Pages: 10

DOI: 10.2174/1573412917666210121151724

Price: $65

Abstract

Background: Omeprazole has poor water solubility, is unstable in acidic solutions and undergoes first-pass metabolism, which results in lowering its bioavailability. A solid Self-Nano Emulsifying Drug Delivery System (SNEDDS) was previously prepared to enhance its dissolution.

Objective: Development and validation of an RP-HPLC method with UV detection for the determination of omeprazole in 0.1 N HCl and in 0.01 M phosphate buffer (pH 7.4).

Methods: Validation was according to the ICH Q2 (R1) guidelines in terms of linearity, accuracy and precision, lower limit of quantification, sensitivity, specificity, and robustness. The developed and validated method was used to study the in-vitro dissolution of the drug from the solid- SNEDDS, commercial products, and the unprocessed drug. The dissolution was studied in 500 ml of 0.1N HCl during the first 2 hours, and 900 mL of 0.01 M phosphate buffer (pH 7.4) during the last hour (37 ± 0.5 °C and 100 rpm).

Results: The method was linear in the range 1-50 μg/ml, accurate and precise as indicated by the ANOVA test. It was specific to the drug and the pharmaceutical excipients did not affect the determination of its concentration. The method was robust to small changes in pH, composition, and flow rate of the mobile phase. The dissolution rate of omeprazole from the Solid-SNEDDS was faster than that from two commercial dosage forms and than the dissolution rate of the unprocessed drug.

Conclusion: The method met the acceptance criteria and was applied successfully in studying the rate of dissolution of the drug.

Keywords: Omeprazole hydrochloride, self-nanoemulsifying drug delivery system, RP-HPLC method, validation, application to dissolution study, in-vitro.

« Previous Next »
Graphical Abstract

[1]
Singh, D.; Alok, S.; Mahor, A.; Kumar, K. Advancement of chitosan-based nanoparticles for targeted delivery of antiulcer drugs. WJPR, 2015, 4(1), 505-518.
[2]
Arshad Ahmed Khan, K.; Aparna, P.; Harathi, P.; Padmanabha Reddy, Y.; Sowmya, C. Ternary solid dispersions of omeprazole for enhancing solubility and dissolution. WJPR, 2015, 4(10), 2402-2412.
[3]
Möschwitzer, J.; Achleitner, G.; Pomper, H.; Müller, R.H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm., 2004, 58(3), 615-619.
[http://dx.doi.org/10.1016/j.ejpb.2004.03.022] [PMID: 15451536]
[4]
El-Badry, M. Improvement of the in vitro release of omeprazole from suppository bases using Kollicoat IR. J. Drug Deliv. Sci. Technol., 2010, 20(5), 391-395.
[http://dx.doi.org/10.1016/S1773-2247(10)50064-9]
[5]
Venna, D.P.; Allam, S.N.; Phanindra, P. Enhancing stability of an anti-ulcer drug through lyophilization technique. IJSRP, 2013, 3(10), 1-13.
[6]
Bozdag, S.; Çalis, S.; Sumnu, M. Formulation and stability evaluation of enteric-coated omeprazole formulations. STP Pharma. Sci., 1999, 9(4), 321-327.
[7]
National Center for Biotechnology Information. Omeprazole compound summary., pubchem.ncbi.nlm.nih.gov/compound/omeprazole
[8]
AstraZeneca medications. Prilosec® delayed release capsules, www.astrazeneca-us.com/medicines/astrazeneca-medications.html#
[9]
Mohammed, S.S.; Pranush, K.V.; Reddy, G.V. Improvement of solubility of omeprazole magnesium by solid dispersion and slugging method. AJRBPS, 2013, 1(2), 83-89.
[10]
Gursoy, R.N.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother., 2004, 58(3), 173-182.
[http://dx.doi.org/10.1016/j.biopha.2004.02.001] [PMID: 15082340]
[11]
Savjani, K.; Gajjar, A.; Savjani, J. Drug solubility: importance and enhancement techniques. ISRN Pharm., 2012, 1-10.
[12]
Karim, S.; Baie, S.H.; Hay, Y.K.; Bukhari, N.I. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process. Pak. J. Pharm. Sci., 2014, 27(3), 425-438.
[PMID: 24811797]
[13]
AstraZeneca UK Limited. Losec® MUPS® Tablets 20mg patient leaflet, www.medicines.org.uk/emc/product/1514/smpc
[14]
Al-Nimry, S.S.; Alkhamis, K.A.; Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharm. Dev. Technol., 2020, 25(5), 588-600.
[http://dx.doi.org/10.1080/10837450.2020.1721536] [PMID: 31976799]
[15]
Kang, W-K.; Kim, D-S.; Kwon, K.I. Advanced method for determination of omeprazole in plasma by HPLC. Arch. Pharm. Res., 1999, 22(1), 86-88.
[http://dx.doi.org/10.1007/BF02976443] [PMID: 10071967]
[16]
Iuga, C.; Moldovan, M.; Popa, A.; Leucuţa, S.E. Validation of HPLC-UV method for analysis of omeprazole in presence of its metabolites in human plasma. Farmacia, 2008, LVI(3), 254-260.
[17]
Zarghi, A.; Foroutan, S.M.; Shafaati, A.; Khoddam, A. HPLC determination of omeprazole in human plasma using a monolithic column. Arzneimittelforschung, 2006, 56(6), 382-386.
[PMID: 16889119]
[18]
Noubarani, M.; Keyhanfar, F.; Motevalian, M.; Mahmoudian, M. Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. J. Pharm. Pharm. Sci., 2010, 13(1), 1-10.
[http://dx.doi.org/10.18433/J3GP4Q] [PMID: 20456825]
[19]
Lou, J.; Yu, L.; Li, J.; Liu, J.; Ding, Q.; Chen, W.; Sun, L.; Zhang, Y. Development and validation of a HPLC method for the estimation of omeprazole in human plasma. Lat. Am. J. Pharm., 2016, 35(2), 239-243.
[20]
Nahar, K.; Joti, J.J.; Ashik Ullah, M.; Hasan, A.; Azad, M.A.K.; Abul Hasnat, A. A simple RP−HPLC method for the determination of omeprazole in human serum and urine: validation and application in pharmacokinetic study. Dhaka Univ. J. Pharm. Sci, 2009, 8(2), 123-130.
[http://dx.doi.org/10.3329/dujps.v8i2.6026]
[21]
Murakam, F.S.; Cruz, A.P.; Pereira, R.N.; Valente, B.R.; Silva, M.A.S. Development and validation of a RP-HPLC method to quantify omeprazole in delayed release tablets. J. Liq. Chromatogr. Relat. Technol., 2007, 30(1), 113-121.
[http://dx.doi.org/10.1080/10826070601034485]
[22]
Darwish, K.M.; Salama, I.; Mostafa, S.; El-Sadek, M. RP-HPLC/pre-column derivatization for analysis of omeprazole, tinidazole, doxycycline and clarithromycin. J. Chromatogr. Sci., 2013, 51(6), 566-576.
[http://dx.doi.org/10.1093/chromsci/bms167] [PMID: 23081968]
[23]
Chaudhry, A.; Malik, T.A.; Ashfaq, K.M.; Akhtar, M.S. A simple HPLC method for the determination of omeprazole in vitro. IJPC, 2012, 2(4), 126-128.
[24]
Krishnaiah, V.; Reddy, Y.V.R. Development and validation of HPLC method for simultaneous determination of omeprazole and domperidone. Pharma Chem., 2012, 4(1), 455-459.
[25]
Gopalakrishnan, S.; Jothy, K.; Dhanalakshmi, K. Analytical method development and validation of HPLC method for the determination of omeprazole in capsule dosage form. Elixir Appl. Chem, 2012, 52, 11283-11286.
[26]
Nataraj, K.S.; Duza, M.B.; Pragallapati, K.; Kumar, D.K. Development and validation of RP-HPLC method for the estimation of omeprazole in bulk and capsule dosage forms. Int. Curr. Pharm. J., 2012, 1(11), 366-369.
[http://dx.doi.org/10.3329/icpj.v1i11.12062]
[27]
Swethanagini, V.; Vasanth Kumar, M. A validated RP HPLC method for simultaneous estimation of omeprazole and cinitapride in combined dosage forms. IJRPC, 2012, 2(4), 1078-1085.
[28]
Baraka, M.M.; Elsadek, M.E.; Ibrahim, A.M. HPLC method for the simultaneous determination of secnidazole, omeprazole and amoxicillin mixture in pure forms and pharmaceutical formulations. AJPAMC, 2014, 2(4), 197-207.
[29]
Salem, H.; Riad, S.M.; Rezk, M.R.; Ahmed, K. Simultaneous determination of Omeprazole, Tinidazole and Clarithromycin in bulk powder and Helicure® tablets by HPLC. J. Chromatograph. Separat. Techniq, 2014, 5, 221.
[http://dx.doi.org/10.4172/2157-7064.1000221]
[30]
Ghantasala, J.P.; Rao, M.P. Method development and validation of RP-HPLC method for the simultaneous estimation of omeprazole and dicyclomine HCl in combined tablet dosage form. IJIPSR, 2016, 4(1), 62-74.
[31]
Kranthi, K.K.; Supriya, D.; Divya, D.; Rani, D.; Munni, G.N. Analytical method development and validation for the estimation of aspirin and omeprazole using RP-HPLC method. ICJPIR, 2017, 4(1), 44-71.
[32]
Sharma, S.; Sharma, M.C. Development and validation of new analyticalmethods for simultaneous estimation of Drotaverine hydrochloride in combination with Omeprazole in a pharmaceutical dosage form. Arab. J. Chem., 2017, 10, S397-S403.
[http://dx.doi.org/10.1016/j.arabjc.2012.09.012]
[33]
Yenduri, G.; Navuluri, S. Analytical high performance liquid chromatography method for estimating the combination of aspirin and omeprazole in bulk and tablet dosage form. Marmara Pharm. J., 2018, 22(4), 502-510.
[34]
Ali, M.M.; Eshtiag Ibrahim, A.; Abdalaziz, M.N. Development and validation for RP-HPLC method of assay of omeprazole capsules formulation. Am. J. Appl. Sci., 2018, 6(1), 1-6.
[http://dx.doi.org/10.11648/j.ajche.20180601.11]
[35]
Varu, N.H.; Patel, P.B. Development and validation of RP-HPLC method for dissolution study of pantoprazole sodium and domperidone in capsule dosage form. World J. Pharm. Pharm. Sci., 2018, 7(5), 930-944.
[36]
Alamin, I.A.; Elbashir, A.A. A new study on Omeprazole spectrophotometric determination using 9- Fluorenylmethyl chloroformate as derivatizating agent. J. Anal. Pharm. Res., 2019, 8(2), 38-43.
[http://dx.doi.org/10.15406/japlr.2019.08.00309]
[37]
Riedel, A.; Leopold, C.S. Quantification of omeprazole degradation by enteric coating polymers: an UV-VIS spectroscopy study. Pharmazie, 2005, 60(2), 126-130.
[PMID: 15739901]
[38]
Nalini, M.V.S.S. Haribabu, B. Stability indicating RP-HPLC method for determination of omeprazole and cinitapride in combined pharmaceutical dosage form. Rasayan J. Chem., 2015, 8(4), 433-442.
[39]
Binnor, A.K.; Mukkanti, K.; Suryanarayana, M.V.; Roy, S.B. A validated stability indicating high performance liquid chromatographic assay method to investigate stability of omeprazole injection in injectable solutions (5% dextrose and 0.9% sodium chloride). J. Pharm. Sci. Res., 2012, 4(3), 1814-1818.
[40]
Rahman, A.; Haque, M.R.; Sultan, Z.; Rahman, M.M.; Rashid, M.A. Enantiomeric determination of omeprazole and esomeprazole by a developed and validated chiral HPLC method and stability studies by microthermal analysis. Dhaka Univ. J. Pharm. Sci, 2017, 16(2), 221-233.
[http://dx.doi.org/10.3329/dujps.v16i2.35261]
[41]
Figueiras, A.; Carvalho, R.A.; Ribeiro, L.; Torres-Labandeira, J.J.; Veiga, F.J.B. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur. J. Pharm. Biopharm., 2007, 67(2), 531-539.
[http://dx.doi.org/10.1016/j.ejpb.2007.03.005] [PMID: 17451924]
[42]
Moore, T.; Smith, A.; Ye, W.; Toler, D.Y.; Westenberger, B.J.; Lionberger, R.; Raw, A.; Yu, L.; Buhse, L.F. Generic omeprazole delayed-release capsules: in vitro performance evaluations. Drug Dev. Ind. Pharm., 2009, 35(8), 917-921.
[http://dx.doi.org/10.1080/03639040802698802] [PMID: 19555236]
[43]
Chakravarthy, K.K.; Younus, M.; Shaik, S.; Pisipati, S.V.V. Formulation and evaluation of enteric coated pellets of omeprazole. Int. J. Drug Dev. Res, 2012, 4(4), 257-264.
[44]
Choudhury, A.; Das, S.; Bahadur, S.; Saha, S.; Roy, A. Formulation and evaluation of omeprazole tablets for duodenal ulcer. Indian J. Pharm. Sci., 2010, 72(4), 491-494.
[http://dx.doi.org/10.4103/0250-474X.73922] [PMID: 21218061]
[45]
Soumya, M.; Chowdary, Y.A.; Pedamallu, G.; Mohan, K.S.K.; Krishna, M.M. Formulation and in vitro evaluation of omeprazole fast dissolving tablets. Int. Res. J. Pharm, 2013, 4(8), 168-171.
[http://dx.doi.org/10.7897/2230-8407.04833]
[46]
Jain, P.; Gupta, R.N.; Shrivastava, S. Formulation and evaluation of mouth dissolving tablets of omeprazole. Int. J. Curr. Pharm. Res., 2016, 8(2), 48-51.
[47]
Dinesh Mohan, S.; Gupta, V.R.M.; Yasam, H.; Jampani, Y.; Yalamanchili, M. Nonaqueous enteric coating application of HPMC and Eudragit L100 on hard gelatin capsules: designed to achieve intestinal delivery. J. Appl. Pharm. Sci, 2015, 5((Suppl 1)), 001-006.
[48]
Liu, F.; Shokrollahi, H. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. Int. J. Pharm., 2015, 485(1-2), 152-159.
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.008] [PMID: 25746736]
[49]
Sundar, V.D.; Nandhakumar, S.; Alekya, C.H.; Dhanaraju, M.D. Formulation and optimization of delayed release mups (multiple unit particulate system) tablets of omeprazole. Pharm. Sin., 2017, 8(2), 16-22.
[50]
Filho, V.J.T.; Andreazza, I.F.; Sato, M.E.O.; Murakami, F.S. Development of a multiparticulate system containing enteric-release mini-tablets of omeprazole. Braz. J. Pharm. Sci., 2014, 50(3), 505-511.
[http://dx.doi.org/10.1590/S1984-82502014000300008]
[51]
Migoha, C.O.; Kaale, E.; Kagashe, G. Formulation development of generic omeprazole 20 mg enteric coated tablets. Pharmacol. Pharm., 2015, 6, 293-301.
[http://dx.doi.org/10.4236/pp.2015.67031]
[52]
Mansuri, N.S.; Parejiya, P.B.; Soniwala, M.M. Exploring use of quality by design (QbD) principles for development of modified release omeprazole pellets. J. Chem. Pharm, 2015, 7(10), 630-639.
[53]
Muthuprasanna, P.; Lathaeaswari, R.; Suriaprabha, K.; Roosewelt, C.; Gopinath, M.; Sreedhar, V.; Babu, A.S. Formulation of delayed release oral dosage forms for omeprazole and it’s in vitro evaluation. MSAIJ, 2007, 3(4), 255-260.
[54]
Manranjan, V.C.; Yadav, D.S.; Jogia, H.A. Quality by design based dissolution test development of omeprazole extended release formulation. Asian J. Pharm. Clin. Res, 2014, 7(5), 150-154.
[55]
Milić, J.; Radojković, B.; Jančić-Stojanović, B.; Drašković, J.; Mirašević, S.; Čalija, B. Investigation of omeprazole stability in oral suspensions for pediatric use prepared extemporaneously from omeprazole capsules. Arh. Farm. (Belgr.), 2017, 67, 14-25.
[http://dx.doi.org/10.5937/arhfarm1701014M]
[56]
Farinha, A.; Bica, A.; Martins, J.M.; Pais, J.P. Dissolution of omeprazole from delayed-release solid oral dosage forms. Drug Dev. Ind. Pharm., 2000, 26(7), 785-790.
[http://dx.doi.org/10.1081/DDC-100101300] [PMID: 10872100]
[57]
Lo, L.; Lu, X.; Lloyd, D. Dissolution testing of a controlled-release capsule formulation: challenges and solutions using a semi-automated dissolution system. Dissolut. Technol., 2013, 20(2), 6-12.
[http://dx.doi.org/10.14227/DT200213P6]
[58]
Storpirtis, S.; Rodrigues, D. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets. Drug Dev. Ind. Pharm, 1998, 24(11), 1101-107.
[http://dx.doi.org/10.3109/03639049809089956]
[59]
Mathew, M.; Gupta, V.D.; Bailey, R.E. Stability of omeprazole solutions at various pH values as determined by high-performance liquid chromatography. Drug Dev. Ind. Pharm., 1995, 21(8), 965-971.
[http://dx.doi.org/10.3109/03639049509026660]
[60]
ICH. Q2 (R1), Validation of analytical procedures: text and methodology ICH Harmonized Tripartite Guideline. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Chicago, USA2005.
[61]
USP 29-NF24. Monograph of omeprazole delayed release capsules, ftp.uspbpep.com/v29240/usp29nf24s0_m58645.html
[62]
Suresh, R.; Anarthanan, S.; Manavalan, R.; Valliappan, K. Aspects of validation in HPLC method development for pharmaceutical analysis-comparison of validation requirements by FDA, USA and ICH. Int. J. Pharm. Sci. Res., 2010, 12, 123-133.
[63]
Karim, S.; Hay, Y.K.; Baie, S.H.; Bukhari, N.I.; Murtaza, G. Study of comparative bioavailability of omeprazole pellets. Acta Pol. Pharm., 2014, 71(3), 463-468.
[PMID: 25265826]
[64]
USP30-NF25. Validation of Compendial Procedures, 2008.www.uspnf.com/uspnf/pub/getPFDocument?usp=30&nf25&supp=2&collection=/db
[65]
Nageswara Rao, R.; Kumar Talluri, M.V.; Narasa Raju, A.; Shinde, D.D.; Ramanjaneyulu, G.S. Development of a validated RP-LC/ESI-MS-MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations. J. Pharm. Biomed. Anal., 2008, 46(1), 94-103.
[http://dx.doi.org/10.1016/j.jpba.2007.09.009] [PMID: 17951020]
[66]
Reddy, L.S.; Reddy, S.L.N.P.; Reddy, G.S. Development and validation of a stability indicating liquid chromatographic method for simultaneous estimation of dutasteride and tamsulosin in combined dosage form. Orient. J. Chem., 2013, 29(4), 1665-1673.
[http://dx.doi.org/10.13005/ojc/290412]
[67]
Tiwari, G.; Tiwari, R. Bioanalytical method validation: An updated review. Pharm. Methods, 2010, 1(1), 25-38.
[http://dx.doi.org/10.4103/2229-4708.72226] [PMID: 23781413]
[68]
Lindholm, J. Development and validation of HPLC methods for analytical and preparative purposes. Thesis, Acta Universitatis Upsaliensis, Uppsala, 2004.
[69]
FDA. Guidance for industry-bioanalytical method validation. Food, Drug Administration Centre for Drug Evaluation and Research, 2001.www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
[70]
Reviewer Guidance: Validation of Chromatographic Method. Center for Drug Evaluation and Research, 1994.www.fda.gov/downloads/Drugs/Guidances/UC M134409.pdf
[71]
CHROMacademy. The theory of HPLC chromatographic parameters, The theory of HPLC chromatographic parameters., www. Chromacademy.com
[72]
Kapoor, D.; Sharma, S.; Patel, M.; Vyas, R.B.; Lad, C. Solubility enhancement and dissolution improvement- liquisolid technique. JDDT, 2013, 3(6), 155-161.
[73]
Onoue, S.; Uchida, A.; Takahashi, H.; Seto, Y.; Kawabata, Y.; Ogawa, K.; Yuminoki, K.; Hashimoto, N.; Yamada, S. Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability. J. Pharm. Sci., 2011, 100(9), 3793-3801.
[http://dx.doi.org/10.1002/jps.22585] [PMID: 21520087]
[74]
Chuang, C-Z.; Ragan, F.A., Jr; Prasad, C. Use of Triethylamine as an Ion-Pairing Reagent. J. Liq. Chromatogr., 1994, 17(11), 2383-2394.
[http://dx.doi.org/10.1080/10826079408013487]
[75]
Park, J.H.; Ryu, Y.K.; Lim, H.J.; Lee, H.S.; Park, J.K.; Lee, Y.K.; Jang, M.D.; Suh, J.K.; Carr, P.W. Effect of triethylamine in the mobile phase on the retention properties of conventional polymeric and horizontally polymerized octadecylsilica in RPLC. Chromatographia, 1999, 49(11), 635-642.
[http://dx.doi.org/10.1007/BF02466905]
[76]
Tzanavaras, P.D. A green HPLC method for the determination of n-acetylcysteine using post-column derivatization with methyl-propiolate. Instrum. Sci. Technol., 2012, 40(2-3), 150-160.
[http://dx.doi.org/10.1080/10739149.2011.651666]
[77]
Yabré, M.; Ferey, L.; Somé, T.I.; Sivadier, G.; Gaudin, K. Development of a green HPLC method for the analysis of artesunate and amodiaquine impurities using Quality by Design. J. Pharm. Biomed. Anal., 2020, 190.
[http://dx.doi.org/10.1016/j.jpba.2020.113507] [PMID: 32846400]
[78]
Duan, X.; Liu, X.; Dong, Y.; Yang, J.; Zhang, J.; He, S.; Yang, F.; Wang, Z.; Dong, Y. A green HPLC method for determination of nine sulfonamides in milk and beef, and its greenness assessment with analytical eco-scale and greenness profile. J. AOAC Int., 2020, 103(4), 1181-1189.
[http://dx.doi.org/10.1093/jaoacint/qsaa006] [PMID: 33241346]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy